Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
06:17pScott Smith's steel guitar love affair plays on  
01:33p$CELG Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multi.. 
10/18Goldman Sachs says to swap Celgene for AbbVie:
1
10/18Celgene Corporation $CELG Given New $167.00 Price Target at BMO Capital Marke.. 
10/18Celgene Corporation downgraded by Zacks Investment Research to hold.  
10/18Bar Harbor Trust Services Has $240,000 Holdings in Celgene Corporation $CELG .. 
10/18Proficio Capital Partners LLC Has $289,000 Stake in Celgene Corporation $CELG.. 
10/18$CELG - Zacks: Analysts Expect Celgene Corporation #CELG to Post $1.88 EPS  
10/18See why @Celgene made this year's list of IBD's first Biotech Innovator Award..
2
10/17On The Fly: Top five analyst initiations $GRPN $HPE $CELG $HIVE $SFM
1
10/17Celgene $CELG PT Raised to $167 at BMO Capital on Positive Data from Phase ST..
1
10/17TUESDAY TOP ANALYST UPGRADES & DOWNGRADES $BIIB $CARB $CELG $EMR $KMI $NF.. 
10/17#investing #daytrading TUESDAY TOP ANALYST UPGRADES & DOWNGRADES $BIIB .. 
10/17Celgene Corporation's buy rating reiterated at J P Morgan Chase & Co.  
10/17Celgene $CELG was initiated a new 'Outperform' at Bernstein with a 12-month t..
2
10/17Celgene Corporation initiated by Sanford C. Bernstein at outperform. $162.00 .. 
10/17Celgene Corporation's PT raised by BMO Capital Markets to $167.00. positive r.. 
10/17$CELG initiated at Outperform at Bernstein. PT $162
7
10/17Horan Capital Advisors LLC. Has $3.64 Million Holdings in Celgene Corporation.. 
10/16Celgene Corporation's buy rating reiterated at Jefferies Group LLC. $160.00 P.. 
10/16Celgene Corporation given $162.00 PT by Cantor Fitzgerald. buy rating.
1
10/16Celgene Corporation : Today's Research Reports on Stocks to Watch: Celgene Co.. 
10/16$CELG Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ul.. 
10/16Celgene Corporation $CELG Price Target Raised to $140.00  
10/16Celgene Corporation $CELG Position Lifted by Fiduciary Financial Services of .. 
10/16Schwab Charles Investment Management Inc. Raises Holdings in Acceleron Pharma.. 
10/15Brokerages Set Acceleron Pharma Inc. $XLRN Price Target at $44.64  
10/15Celgene Corporation $CELG Holdings Decreased by BRITISH COLUMBIA INVESTMENT M.. 
10/15$CELG - Alpine Woods Capital Investors LLC Invests $1.10 Million in Celgene C.. 
10/15$CELG - Ridgewood Investments LLC Maintains Position in Celgene Corporation #.. 
10/14$CELG Information for Celgene Corporation From our Stock News Alerts App 
10/14United Asset Strategies Inc. Takes Position in Celgene Corporation $CELG  
10/14Celgene Corporation $CELG Position Raised by Abbrea Capital LLC  
10/13Acceleron Pharma Inc. $XLRN Shares Bought by Tudor Investment Corp ET AL  
10/13Investors Buy Celgene Corporation $CELG on Weakness  
10/13Celgene's Steady Progression  
10/12SWING TRADE ALERT: Recent $CELG technical alerts: Calm After Storm plus 10 mo.. 
10/12Acceleron Pharma initiated by HC Wainwright at buy. $57.00 PT.  
10/12H.C. Wainwright Believes Acceleron Pharma (NASDAQ: XLRN) Still Has Room to Gr.. 
10/12Celgene Corporation $CELG Shares Sold by Adirondack Trust Co.  
10/11RECAP 10/11 +Chatter: $ARNC $CELG -Chatter:
1
10/10Strategic Research Analysis ­ Positioning to Benefit on  Abbott, Rite Aid, Kr.. 
10/10ValuEngine Upgrades Alliqua BioMedical, Inc. $ALQA to Hold  
10/10Granite Investment Partners LLC Sells 3 Shares of Celgene Corporation $CELG  
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene  
10/10BRIEF-Evotec achieves first milestone in neurodegeneration alliance with Celg.. 
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene: H.. 
10/10Evotec Achieves First Milestone in Neurodegeneration Alliance with Celgene  
10/10BRIEF-Evotec receives $5 million milestone in Celgene alliance  
10/10EVOTEC ACHIEVES FIRST MILESTONE IN NEURODEGENERATION ALLIANCE WITH CELGENE  
More tweets
Qtime:402
Financials ($)
Sales 2017 13 241 M
EBIT 2017 7 523 M
Net income 2017 4 348 M
Debt 2017 3 768 M
Yield 2017 -
P/E ratio 2017 24,31
P/E ratio 2018 18,77
EV / Sales 2017 8,39x
EV / Sales 2018 6,86x
Capitalization 107 B
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 155 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION18.51%107 315
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214